Левамизол-индуцированная лейкоэнцефалопатия: редкий случай побочного действия препарата

Левамизол – противопаразитарное лекарственное средство, широко использующееся в клинической практике. Одним из редких побочных действий препарата является развитие левамизол-индуцированной мультифокальной воспалительной лейкоэнцефалопатии, которая прогрессирует через 2–8 нед после лечения и характеризуется демиелинизацией головного мозга и поражением белого вещества. В статье описан случай левамизол-индуцированной лейкоэнцефалопатии, которую необходимо дифференцировать с рассеянным склерозом, острым рассеянным энцефаломиелитом и оптиконейромиелитом.

1. Howelland M, Prevenier W. From reliable sources: an introduction to historical methods. Cornell University Press; 2001: 77 pp.

2. Thompson JS, Herbick JM, Klassen LW, et al. Studies on levamisole-induced agranulocytosis. Blood. 1980; 56(3): 388–96.

3. Scheinfeld N, Rosenberg JD, Weinberg JM. Levamisole in dermatology: a review. Am J Clin Dermatol. 2004; 5(2): 97–104. https://doi.org/10.2165/00128071-200405020-00004.

4. Moertel CG, Fleming TR, Macdonald JS, et al. Levamisole and fluorouracil for adjuvant therapy of resected colon carcinoma. New Engl J Med. 1990; 322(6): 352–8. https://doi.org/10.1056/NEJM199002083220602.

5. Wolford A, McDonald TS, Eng H, et al. Immune-mediated agranulocytosis caused by the cocaine adulterant levamisole: a case for reactive metabolite(s) involvement. Drug Metab Dispos. 2012; 40(6): 1067–75. https://doi.org/10.1124/dmd.112.045021.

6. Rongioletti F, Ghio L, Ginevri F, et al. Purpura of the ears: a distinctive vasculopathy with circulating autoantibodies complicating long-term treatment with levamisole in children. Br J Dermatol. 1999; 140(5): 948–51. https://doi.org/10.1046/j.1365-2133.1999.02833.x.

7. Karch SB, Mari F, Bartolini V, Bertol E. Aminorex poisoning in cocaine abusers. Int J Cardiol. 2012; 158(3): 344–6. https://doi.org/10.1016/j.ijcard.2011.06.105.

8. WHO model list of essential medicines – 21st list, 2019. Available at: https://www.who.int/publications/i/item/WHOMVPEMPIAU2019.06 (accessed 03.11.2024).

9. Campillo JT, Eiden C, Boussinesq M, et al. Adverse reactions with levamisole vary according to its indications and misuse: a systematic pharmacovigilance study. Br J Clin Pharmacol. 2022; 88(3): 1094–106. https://doi.org/10.1111/bcp.15037.

10. Larocque A, Hoffman RS. Levamisole in cocaine: unexpected news from an old acquaintance. Clin Toxicol. 2012; 50(4): 231–41. https://doi.org/10.3109/15563650.2012.665455.

11. Midthun KM, Nelson LS, Logan BK. Levamisole – a toxic adulterant in illicit drug preparations: a review. Ther Drug Monit. 2021; 43(2): 221−8. https://doi.org/10.1097/FTD.851.

12. Zakharova M, Zakroyshchikova I, Kozlova A, et al. Levamisole-induced leukoencephalopathy in Russia: analysis of 30 cases. Curr Drug Saf. 2022; 17(4): 319–26. https://doi.org/10.2174/1574886317666211224121517.

13. Brunt TM, van den Berg J, Pennings E, Venhuis B. Adverse effects of levamisole in cocaine users: a review and risk assessment. Arch Toxicol. 2017; 91(6): 2303–13. https://doi.org/10.1007/s00204-017-1947-4.

14. Wu VC, Huang JW, Lien HC, et al. Levamisole-induced multifocal inflammatory leukoencephalopathy: clinical characteristics, outcome, and impact of treatment in 31 patients. Medicine. 2006; 85(4): 203–13. https://doi.org/10.1097/01.md.0000230250.95281.60.

15. Hook CC, Kimmel DW, Kvols LK, et al. Multifocal inflammatory leukoencephalopathy with 5-fluorouracil and levamisole. Ann Neurol. 1992; 31(3): 262–7. https://doi.org/10.1002/ana.410310306.

16. Fassas AB, Gattani AM, Morgello S. Cerebral demyelination with 5-fluorouracil and levamisole. Cancer Invest. 1994; 12(4): 379–83. https://doi.org/10.3109/07357909409038226.

17. Kimmel DW, Wijdicks EF, Rodriguez M. Multifocal inflammatory leukoencephalopathy associated with levamisole therapy. Neurology. 1995; 45(2): 374–6. https://doi.org/10.1212/wnl.45.2.374.

18. Luppi G, Zoboli A, Barbieri F, et al. Multifocal leukoencephalopathy associated with 5-fluorouracil and levamisole adjuvant therapy for colon cancer. A report of two cases and review of the literature. The INTACC. Intergruppo Nazionale Terpia Adiuvante Colon Carcinoma. Ann Oncol. 1996; 7(4): 412–5. https://doi.org/10.1093/oxfordjournals.annonc.a010610.

19. Liu HM, Hsieh WJ, Yang CC, et al. Leukoencephalopathy induced by levamisole alone for the treatment of recurrent aphthous ulcers. Neurology. 2006; 67(6): 1065–7. https://doi.org/10.1212/01.wnl.0000237344.06122.79.

20. Xu N, Zhou W, Li S, et al. Clinical and MRI characteristics of levamisole-induced leukoencephalopathy in 16 patients. J Neuroimaging. 2009; 19(4): 326–31. https://doi.org/10.1111/j.1552-6569.2008.00344.x.

21. Figueredo AT, Fawcet SE, Molloy DW, et al. Disabling encephalopathy during 5-fluorouracil and levamisole adjuvant therapy for resected colorectal cancer: a report of two cases. Cancer Invest. 1995; 13(6): 608–11. https://doi.org/10.3109/07357909509024930.

22. Cossaart N, SantaCruz KS, Preston D, et al. Fatal chemotherapy-induced encephalopathy following highdose therapy for metastatic breast cancer: a case report and review of the literature. Bone Marrow Transpl. 2003; 31(1): 57–60. https://doi.org/10.1038/sj.bmt.1703768.

23. Chastel C, Mabin D. Encephalopathies after levamisole therapy. Neurology. 1996; 46(1): 288. https://doi.org/10.1212/wnl.46.1.288.

24. Zheng R. Differential diagnosis of delayed encephalopathy induced by anthelmintic imidazoles. Zhonghua Nei Ke Za Zhi. 1995; 34(7): 468–71 (in Chinese).

25. Lucchinetti CF, Kimmel DW, Pavelko K, Rodriguez M. 5-Fluorouracil and levamisole exacerbate demyelination in susceptible mice infected with Theiler's virus. Exp Neurol. 1997; 147(1): 123–9. https://doi.org/10.1006/exnr.1997.6598.

26. Thompson AJ, Banwell BL, Barkhof F, et al. Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. Lancet Neurol. 2018; 17(2): 162–73. https://doi.org/10.1016/S1474-4422(17)30470-2.

27. Dobson R, Ramagopalan S, Davis A, Giovannoni G. Cerebrospinal fluid oligoclonal bands in multiple sclerosis and clinically isolated syndromes: a meta-analysis of prevalence, prognosis and effect of latitude. J Neurol Neurosurg Psychiatry. 2013; 84(8): 909–14. https://doi.org/10.1136/jnnp-2012-304695.